Stockscreener 앱 받기
1.33
0.76%
0.01
시간 외 거래:
1.37
0.04
+3.01%
전일 마감가:
$1.32
열려 있는:
$1.32
하루 거래량:
29,673
Relative Volume:
0.04
시가총액:
$3.00M
수익:
-
순이익/손실:
$-6.91M
주가수익비율:
-0.408
EPS:
-3.26
순현금흐름:
$-6.14M
1주 성능:
+7.26%
1개월 성능:
-22.98%
6개월 성능:
-63.76%
1년 성능:
-73.55%
1일 변동 폭
$1.2711
$1.38
1주일 범위
$1.22
$1.49
52주 변동 폭
$1.22
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
GLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.33 | 3.00M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-05-22 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 개시 | Craig Hallum | Buy |
| 2020-01-30 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 개시 | Canaccord Genuity | Buy |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-08-02 | 재확인 | Maxim Group | Buy |
| 2018-07-13 | 개시 | Stifel | Buy |
| 2018-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2018-02-14 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 개시 | ROTH Capital | Buy |
| 2017-08-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 재확인 | Maxim Group | Buy |
| 2016-08-01 | 재확인 | Maxim Group | Buy |
| 2016-07-06 | 재개 | ROTH Capital | Buy |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
| 2015-05-06 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - Yahoo Finance
Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India
Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Galmed Pharmaceuticals Ltd (GLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.71%
자본화:
|
볼륨(24시간):